March 18, 2024 |
We’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put the idea of in-person meetings being superior to rest.

Whether we’re talking offices, medical congresses, or advisory board meetings, the term “hybrid” is often used to signal the ideal state. The place where everyone’s needs are being met. The best of both worlds. In the era of digital transformation, it is predicted that 2024 will be the year that finally cements hybrid meetings as the norm (1), with all-virtual meetings continuing to be a popular option. Yet, some people are holding onto the idea of in-person meetings being superior. In this article, we’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put this idea to rest.
I’ve written and talked about the blindspots of in-person meetings for over 16 years now, but it’s only been in the past few years that the benefits of virtual engagements have gained mainstream acceptance. There are multiple reasons why in-person-only meetings should be laid to rest, including, but not limited to, the facts that they are:
Specifically for advisory boards and other insight-gathering initiatives, the in-person-only approach comes with additional pain points such as:
Most important, though, is the fact that participants don’t want only in-person meetings. Based on our survey of hundreds of healthcare provider advisors in 2022–2023, over three-quarters stated that they prefer virtual/hybrid meetings, with the convenience and flexibility of digital meetings rated as the top benefits…
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
Munther Baara, VP Product Strategy and Innovation at EDETEK, discusses all things clinical trials. Especially, we discuss the current gaps and the impact of COVID-19 on the way Pharma approaches…
Cassie Solomon, CEO of The New Group Consulting, dives into the future of innovation, digital technologies, and systems thinking in healthcare. Among many other things, we discuss how organizations can prepare…
A customer story
Laura Towart, Founder & CEO of My Personal Therapeutics, discusses her company’s approach to precision medicine, the barriers patients with cancer face when trying to access personalized treatments, and how…
Kim Shah, CEO of KnowYourMeds, explores digital health, AI, telemedicine, health literacy, and how to ensure a safe return to work amidst the ongoing COVID-19 pandemic. We also dive into…
Dr. Oscar Segurado, Chief Medical Officer at ASC Therapeutics, dives into advanced gene therapies, gene editing, and personalized medicine. We also explore the many different hats he wears as CMO, consultant,…
John Leombruno, CEO of OkRx, shares how his company is working to improve PSP strategy and operations in Canada. He also discusses the impact of COVID-19 on PSPs, digital transformation, clinical…
Chad Walsh, CEO of Sciteline, dives into virtual trials, including their benefits, barriers, and impact on patient-centricity. Among other things, we will discuss data privacy concerns, the role of digital…
Owen Muir, MD, CIO at Brooklyn Minds, explores the secondary effects of COVID-19 on mental health conditions, along with techniques such as deep Transcranial Magnetic Stimulation (dTMS), Mentalization-Based Treatment (MBT), and…
COVID-19 has impacted every aspect of our lives, from the way we shop for groceries to the way we conduct work and interact with healthcare providers and our families.
